Skip to main content

Exact, OncoMethylome Pen Two-Part Deal to Sell CRC-Screening Tests, Services in Europe, N. America

NEW YORK (GenomeWeb News) — OncoMethylome Sciences and Exact Sciences today said they plan to advance the sale of stool-based colorectal cancer-screening technologies through service labs in Europe and North America. 
 
The agreement calls for Exact to grant OncoMethylome non-exclusive rights to its DNA-stabilization, -isolation, and -extraction technology for stool-based CRC-screening tests in Europe.
 
In exchange, OncoMethylome will pay royalties to Exact based on sales.
 
Separately, OncoMethylome will sell reagents to Exact, which may use them in stool-based CRC screening services in North America.
 
The reagents will enable Exact to detect methylation at certain DNA markers using MSP technology. The terms of the agreement also call for OncoMethylome to sell reagents to Exact’s commercial partners, subject to their negotiation with OncoMethylome.
 
Further financial details of the license and supply agreements were not disclosed. 

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.